Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease

Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease

(2013) Simon R.W. Stott et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Trophic Factor Gene Therapy for Parkinson's Disease

(2013) Jeffrey H. Kordower et al.   MOVEMENT DISORDERS

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

(2013) Christopher D. Herzog et al.   NEUROBIOLOGY OF DISEASE

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

(2013) R. T. Bartus et al.   NEUROLOGY

Mechanisms of dopamine transporter regulation in normal and disease states

(2013) Roxanne A. Vaughan et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The Physiology, Signaling, and Pharmacology of Dopamine Receptors

(2011) J.-M. Beaulieu et al.   PHARMACOLOGICAL REVIEWS

Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains

(2010) Raymond T. Bartus et al.   MOVEMENT DISORDERS

Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys

(2009) Jamie L. Eberling et al.   HUMAN GENE THERAPY

Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys

(2009) Louisa C. Johnston et al.   HUMAN GENE THERAPY

Activin A Is Essential for Neurogenesis Following Neurodegeneration

(2009) Andrea Abdipranoto-Cowley et al.   STEM CELLS